Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2, has some activity against brain metastases (BMs) from HER2-positive metastatic breast cancer (HER2+ MBC), especially when combined with capecitabine [1, 2] .
Given low molecular weight and lipophilic nature, lapatinib is believed to cross the blood-brain barrier (BBB) and penetrate the central nervous system (CNS) . In an experimental model of HER2+ BMs, a limited distribution of lapatinib was observed in healthy brain tissue, but drug accumulation in tumor deposits was about 7-9 fold higher than surrounding normal brain. This was probably due to compromised functions of BBB in BMs resulting in an increased blood vessel permeability [3] . These preclinical data are consistent with the results of a clinical trial showing clinically relevant concentrations of lapatinib in BMs from HER2+ breast cancer [4] .
Drug concentration in cerebrospinal fluid (CSF) is generally considered a surrogate for predicting concentration in the brain. A high ratio of CSF/plasma drug concentration indicates a high distribution in the brain, whereas a low ratio means poor penetration through BBB and possibly lack of activity within CNS.
To date, no data on lapatinib concentration in CSF have been reported. Even in the LANDASCAPE phase II trial with lapatinib and capecitabine, CSF concentration of lapatinib was not assessed, and this was emphasized by the authors themselves as one of the limitations of their study [1] .
We assessed lapatinib concentration in CSF and plasma of two women affected by HER2+ MBC and BMs treated with lapatinib and capecitabine ( Table 1) . A written informed consent was obtained from each patient before samples collection for research purposes. Plasma and CSF samples were collected 5 h after a lapatinib single oral dose of 1250 mg. Plasma concentration was evaluated by high-pressure liquid chromatography (HPLC) and ultraviolet detection. CSF concentration was assessed by HPLC coupled with mass spectrometry. Because lapatinib is 99.9% bounded to proteins, we also measured plasma and CSF protein concentration.
Lapatinib concentration was 1515 and 3472 ng/ml in the plasma, and 1.3 and 4.5 ng/ml in the CSF of the two patients, respectively (Table 1) . Despite the low drug concentration in CSF, the two patients had a brain stable disease for 14 and 19 months, respectively (Table 1 ).
In conclusion, we found low concentrations of lapatinib in CSF with a low ratio of CSF/plasma concentration for both patients. Our findings are consistent with the poor solubility of lapatinib in the CSF watery environment and with the low concentration of proteins in the CSF. Based on our data, lapatinib concentration in CSF may not be a reliable surrogate of its distribution in CNS. Positron emission tomography (PET) with radiolabeled lapatinib seems to be a more suitable method to assess drug access to cerebral metastases, as suggested by the results of a clinical trial recruiting three patients with HER2+ MBC and BMs. In this study, 11 C-lapatinib uptake was higher in cerebral metastases than in normal brain [5] . The uptake of 11 Clapatinib might indicate possible activity against BMs, and PET with Bone mineral density screening should be routine in lymphoma patients Drs Paccou et al. noted that 'Adult patients with known lymphoma receiving chemotherapy experienced significant [bone mineral density] BMD loss at 1 year' [1] . Their conclusions were drawn based upon 32 assessable patients with BMD better than −2.5 by T or Z scores. We find these data to be highly interesting as these results are similar to our randomized phase III clinical trial which evaluated the benefit of zoledronic acid (ZA) in the same lymphoma patient population [2] . In our trial, the patients who received ZA had stable BMD during the observation period. The 29 assessable patients in our control arm (calcium + Vitamin D only), analogous to the group presented by Paccou, showed bone loss. Bone biomarkers (urine N-telopeptide and serum bone-specific alkaline phosphatase) were higher in the control arm at all intervals after treatment. Our study differed in the inclusion criteria as we excluded patients with BMD worse than −2.0. We also screened and excluded patients for a variety of endocrine (hypovitaminosis D, hypogonadism, etc.) or dental issues.
Since 2007, we have reported osteopenia and osteoporosis as common findings in untreated NHL patients [3] . Further supporting these data is a 2009 report on bone loss in lymphoma patients from Anargyrou et al. [4] . Based on these three independent datasets, it is our opinion that we should routinely check baseline BMD and use prophylaxis in appropriately selected patients with calcium, vitamin D and ZA (or potentially other bone directed therapies) to prevent this predictable side-effect from lymphoma treatment. 
